You are here:

Leading rheumatologist appointed new chair of SMC

Leading rheumatologist appointed next chair of Scottish Medicines Consortium. 

One of Scotland’s leading rheumatologists has been appointed as the next chair of the Scottish Medicines Consortium (SMC).

Dr Alan MacDonald, who has been a Consultant Rheumatologist in Aberdeen since 1996 and is a former president of the Scottish Society for Rheumatology, will take up the post in April 2017. He will succeed Professor Jonathan Fox, who has held the post since 2014.

Dr MacDonald has been a member of NHS Grampian’s Area Drugs and Therapeutics Committee since 2007 and has been a member of SMC since then. He joined the SMC executive team as Co-Vice Chair of the New Drugs Committee (NDC) in June 2013 and has been Chair of the NDC from January 2014. He has also served as Co-Vice Chair of the SMC since January 2014. 

He said:

“I’m delighted to be appointed as chair of SMC. We’ve seen a number of changes over the last few years and Professor Fox has successfully led the Committee through this period, resulting in a body that is stronger and more committed than ever to making clinically and cost effective new medicines available for routine use by the people of Scotland.” 

Professor Fox said:

 “Alan is an excellent choice to lead the SMC. He has proved to be a valuable member of SMC over the years and I am confident that the Committee will continue to flourish under his leadership. I wish him every success.”

Dr MacDonald’s appointment was welcomed by Dr Dame Denise Coia, Chair of Healthcare Improvement Scotland, the parent body of SMC. 

She said:

“I’d like to congratulate Dr MacDonald on his appointment. As Co-Vice Chair of SMC, he has supported Professor Fox in leading the Committee through a period of significant change, and I have no doubt he will prove to be a valuable chairman. 

“Healthcare Improvement Scotland thanks Professor Fox for his work as chair over the past three years and wishes him every success for the future.”